

RESEARCH ARTICLE

Open Access

Prevalence of microalbuminuria and diagnostic value of dipstick proteinuria in outpatients from HIV clinics in Bukavu, the Democratic Republic of Congo

Mannix Imani Masimango^{1,2,6*}, Ernest Kiswaya Sumaili¹, Michel Jadoul³, Pierre Wallemacq⁴, Dieudonné Kanigula Mubagwa⁵, Rissassy Jean-Robert Makulo¹, François Bompeka Lepira¹ and Nazaire Mangani Nseka¹

Abstract

Background: Microalbuminuria is a marker of early kidney disease and high cardiovascular risk in various populations, including HIV positive patients. However, the diagnostic value of qualitative (dipstick) proteinuria and the burden of microalbuminuria in HIV positive patients living in sub-Saharan Africa are relatively unclear.

Methods: In a cross-sectional study, 235 HIV- positive outpatients were screened for proteinuria in 3 HIV-clinics in Bukavu. A spot urine sample from each subject was tested both by a dipstick and albumin-creatinine-ratio (ACR) assay. The performance of dipstick proteinuria exceeding 1+ was compared with that of microalbuminuria (≥ 30 mg/g creatinine).

Results: The prevalence of microalbuminuria and dipstick proteinuria $\geq (1+)$, $\geq (2+)$ and $\geq (3+)$ was 11%, 41%, 3.5% and 0.7%, respectively.

Compared to microalbuminuria, the dipstick (proteinuria of 1+ or greater) had an overall sensitivity of 60% and a specificity of 61%. The positive predictive value was 15.4% and the negative predictive value 92.8%.

Conclusion: Proteinuria is highly prevalent in HIV positive patients. The limited sensitivity and specificity of the dipstick to detect significant microalbuminuria make it unattractive as a screening tool in HIV positive patients.

Keywords: Dipstick proteinuria, Albumin/creatinine ratio, Diagnostic value, HIV-patients

Background

The prevalence of chronic kidney disease (CKD) is high in the African HIV infected population [1,2] where late referral to hospital and scarce possibilities of renal replacement therapy are well known. The early detection of CKD would provide the opportunity to implement strategies known to slow CKD progression [3,4]. Thus, the identification of overt proteinuria or even microalbuminuria, might be an important tool for the early detection of CKD in HIV-infected individuals [5,6]. The

Infectious Diseases Society of America (IDSA) guidelines on the management of chronic kidney disease in HIV-positive patients recommend the use of a urine dipstick, with a threshold for detection of renal disease at 1+ proteinuria. When dipstick is ≥ 1 , a quantification of proteinuria is recommended. Currently, this relies on the albumin/creatinine ratio (ACR) measured on a spot of urine [7,8]. However, in many emerging countries, the dipstick remains the only method used for the evaluation of proteinuria. Nevertheless, it is recognized that dipsticks may have poor sensitivity in detecting low-grade proteinuria [9].

The purpose of the current study was to evaluate the prevalence of proteinuria in HIV-positive patients and to assess the diagnostic value of urinary dipstick as screening test for proteinuria compared with the albumin/creatinine ratio (ACR).

* Correspondence: masimax2003@yahoo.fr

¹Department of Medicine, Université Catholique de Bukavu, Bukavu, DR Congo

²Nephrology Unit, Department of Medicine, Université de Kinshasa, Kinshasa, DR Congo

Full list of author information is available at the end of the article

Methods

Written informed consent for participation in the study was obtained from participants.

A cross-sectional survey was conducted in March and April 2012 in 3 outpatient HIV-clinics in Bukavu, the main town in the eastern rural part of the Democratic Republic of Congo (DRC).

Two hundred and sixty consecutive HIV-1 positive adults (≥ 18 years) who routinely attended one of the clinics during the survey period were screened.

Single spot urine specimens were collected in the morning. Urine samples containing blood (1+ or greater), white blood cells (1+ or greater) and/ or nitrites were excluded. This left 235 subjects in whom, both a urine dipstick test and a urine albumin to creatinine ratio measurement were performed (ACR). The results of urine dipstick (Multistix 8 SG[®], Siemens Healthcare Diagnostics, France) were read as either negative (<30 mg/dl) or positive at 1+, 2+, 3+ or greater, corresponding approximately to protein concentrations of 30, 100 mg/dl, 300 and ≥ 2000 mg/dl. ACR was performed using the DCA Vantage[™] analyzer (Siemens Healthcare Diagnostics Pty Ltd., 885 Mountain Highway, Australia), utilizing an immunoassay method for Albumin. Microalbuminuria was defined by a urinary albumin-to-creatinine ratio (ACR) 30–299 mg/g and macroalbuminuria by an ACR >300 mg/g. The diagnostic value (sensitivity, specificity, positive predictive value, negative predictive value) of dipstick $\geq 1+$ and $\geq 2+$ to detect micro or macro albuminuria was thus assessed.

Statistical tools

The processing and data analysis were performed using SPSS software Windows version 18.0 and MedCalc 9.2.1.0.

Quantitative albuminuria expressed as ACR was subdivided into three sub-groups: <30 mg/g (normoalbuminuria), 30 to 299 mg/g (microalbuminuria) and ≥ 300 mg/g (macroalbuminuria), and compared with the respective results of the dipstick on the same sample.

The diagnostic value (sensitivity, specificity, positive predictive value, negative predictive value) of the dipstick 1+ or greater (>30 mg/dl) was thus studied. The cutoff of 1+ was chosen on the basis of IDSA's recommendations.

Ethical issues

Permission obtained from the Ethics Committee of the school of Medicine of the Catholic University of Bukavu (Commission Institutionnelle d'Ethique, 09 juin 2012).

Results

A total of 260 patients were contacted. Twenty-five had to be excluded because of hematuria ($n = 12$), detection of nitrites in urine ($n = 8$) or leucocyturia ($n = 5$). The 25

excluded patients had demographic characteristics similar to those of the 235 included patients.

A total of 235 patients were thus included, of whom 179 (76.2%) were on antiretroviral therapy. Baseline data are provided in Tables 1, 2 and 3. All patients were African. Median age was 40 years (IQR 18–74) and 73.2% were women.

Median CD4 cell count was 480 cells /mm³ (IQR 10–1202). The overall prevalence of proteinuria according to ACR was 10.6% (95% CI 6.67– 14.53), 8.9% for microalbuminuria (ACR 30–300 mg/g) and 1.7% for macroalbuminuria (ACR >300 mg/g). In contrast, the prevalence of dipstick urine protein (1+), (2+) and (3+) were 37%, 3.4% and 0.9%, respectively.

Regarding the intensity of proteinuria, no difference was observed between the groups receiving antiretroviral versus ART naive patients.

The 235 paired dipstick and quantitative results are displayed in Table 4.

Seventy-six (36.2%) of 210 patients with urine ACR < 30 mg/g had a positive urine dipstick results (false-positive result $\geq 1+$). Furthermore, 10 (47.6%) of 21 patients with abnormal low-level albuminuria (UACR 30 to 299 mg/g) had negative urine dipstick results (false-negative result: 1+).

In comparison with ACR > 30 mg/g, urine dipstick had an overall sensitivity and specificity of 60% and 61%, respectively. At a prevalence of proteinuria of 10.6%, the positive predictive value of positive urine dipstick for ACR >30 mg/g was 15.4% and the negative predictive value 92.8%.

Discussion

The purposes of this study were to determine the prevalence of microalbuminuria in an HIV-infected clinic population in DRC and the performance of the dipstick urine test compared to the ACR. Approximately three quarter of the subjects were women, consistent with other data showing a feminization of HIV infection, particularly in Africa [10,11].

In the present study, the prevalence of proteinuria with dipstick test ($\geq 1+$) was 41.3%. Cohort studies suggest that approximately 30% of HIV-positive individuals have proteinuria ($\geq 1+$). Similar results are reported by Fabian *et al.* in South Africa (44%) [12] and Jao *et al.* in Cameroon (39%) [13]. However, Struik *et al.* [14] and Longo *et al.* [15] reported a lower prevalence, 23 and 21% respectively. Furthermore, the prevalence of quantitative proteinuria defined as ACR ≥ 30 mg/g was 10.6%. This prevalence is similar to that of earlier reports varying from 6% to 30% in the HIV-infected, which is three to five times higher than in the general population [16–19]. Differences in methodological approach and in clinical profile of patients could probably explain the variability of results between studies.

Table 1 General characteristics of studied population

Variables	Whole group n = 235	HAART subjects n = 179	ART naive subjects n = 56	p
Female, %	172 (73,2)	127 (54)	45 (19,1)	0,0001
Age (years, median)	40,0 ± 10,7	42,3 ± 10,6	35 ± 9,7	< 0,0001
Family history of:				
- DM	48 (20,4)	41 (17,4)	7 (3)	0,06
- Hypertension	72 (30,6)	54 (23,0)	18 (7,7)	0,28
- Obesity	50 (21,3)	39 (16,6)	11 (4,7)	0,61
- CKD	22 (9,4)	15 (6,4)	7 (3,0)	0,49
Comorbidities				
- DM	4 (1,7)	4 (1,7)	0 (0)	0,597
- Hypertension	110(46,8)	87 (37,0)	23 (9,8)	0,02
Level of education < 6 years	113 (48,9)	79 (34,2)	34 (14,7)	0,05
Marital status:				
- Married	104 (55,7)	78 (43)	26 (12,8)	0,01
- widow	131 (55,7)	101 (43)	30 (12,8)	0,005
History of smoking	28 (11,9)	21 (8,9)	7 (3)	0,73
History of alcohol consumption	107 (45,5)	82 (34,9)	25 (10,6)	0,036
History of medicinal plants use	29 (12,3)	19 (8,1)	10 (4,3)	0,69
History of NSAIDS use	49 (20,9)	39 (16,6)	10 (4,3)	0,62

Data are expressed as absolute or relative frequencies or mean plus the standard deviation (SD) as appropriate.

Table 2 Clinical characteristics of subjects

Variables	Whole group n = 235	HAART subjects n = 179	ART naive subjects n = 56	p
Known HIV infection duration (years)	4,7 ± 3,2	5,3 ± 3,04	2,8 ± 2,9	<0,0001
Duration of HAART (months)	NA	46,2 ± 30,08	NA	
WHO stage for HIV clinical disease:				
- Stage 1	25 (10,6)	12 (5,1)	13 (5,5)	0,39
- Stage 2	53 (22,6)	21 (8,9)	32 (13,6)	0,93
- Stage 3	140 (59,6)	129 (54,9)	11 (4,7)	0,0039
- Stage 4	17 (7,2)	17 (7,2)	0	<0,0001
Body mass index (kg/m ²)	22,3 ± 3,8	22,5 ± 3,9	21,7 ± 3,4	0,198
SBP (mmHg)	118,82 ± 20,89	120,58 ± 21,7	113,2 ± 16,7	0,023
DBP (mmHg)	77,7 ± 14,02	79,8 ± 14,7	71,8 ± 11,6	0,0002
HAART regimen:				
AZT + 3TC + NVP	NA	164 (94,8)	NA	
d4T + 3TC + NVP	NA	3 (1,6)	NA	
ABC + DDI + Lp/r	NA	9 (5)	NA	
TDF + 3TC + EFV	NA	3 (1,6)	NA	

HTA = hypertension; BMC = body mass index; SBP = Systolic blood pressure; DBP = diastolic blood pressure; CKD = chronic kidney disease; HAART: Highly active antiretroviral therapy. NA: not applicable; d4T: stavudine, 3TC: lamivudine, NVP: nevirapine, ABC: abacavir, DDI: didanosine, Lp/r : lopinavir/ritonavir, EFV: efavirenz, TDF: tenofovir.

Table 3 Biological characteristics of subjects

Variable	Whole group	HAART group	ART naïve group	p
Fasting glycaemia	103,5 ± 14,4	104,2 ± 15,1	100,3 ± 10,6	0,27
Hemoglobin	13,3 ± 2,0	13,5 ± 1,9	12,7 ± 2,2	0,01
HBs Ag positive	5 (1,9)	5 (2,1)	0 (0)	0,44
Anti HCV positive	3 (1,2)	1 (0,4)	2(0,9)	<0,0001
CD4 (cells/mm ³ increment):				
- < 200	22 (10,7)	14 (6,8)	8 (3,9)	0,50
- 200-499	96 (46,8)	80 (39)	16 (7,8)	0,034
- > 500	87 (42,4)	66 (32,2)	21 (10,2)	0,089

Variables are absolute numbers and relative frequencies or means plus the standard deviation (SD) as appropriate. CD4: cluster of differentiation.

Although, this study did not address the specific causes of proteinuria in individual subjects, it is likely that proteinuria is related to HIV itself. Experimental studies demonstrate a direct impact of viral components (gp120, TAT) on the endothelium, as they lead to the expression of adhesion molecules (intercellular adhesion molecule [ICAM], E-selectin), a prothrombotic state (increase of von Willebrand factor, plasminogen activator inhibitor-[PAI-]1, tissue plasminogen activator [t-PA], tissue factor). In addition, soluble adhesion molecules (selectin, ICAM) were found to be increased in HIV-infected persons [20]. HIV-associated nephropathy (HIVAN) is the commonest biopsy finding among patients with HIV infection who present with proteinuria. Han *et al.* reported that 25% of naïve HIV-positive black patients (without hypertension, diabetes and with serum creatinine < 250 µmol/L), have microalbuminuria, and that HIVAN was found in 86% of the subset of such patients with persistent microalbuminuria [19].

The results of our study suggest that the urine dipstick may not be an adequate tool for screening for proteinuria in HIV-positive patients. As a screening test, the sensitivity (60%) and specificity (61%) of a single dipstick is poor. In fact, at lower levels of proteinuria (30 to 299 mg/g), a threshold of 1+ dipstick had a false-negative rate of 47.6%. Therefore, nearly 1 in 2 patients with proteinuria in this range may not be recognized and may have delayed workup and treatment. In addition, the proportion of false positives was 36%. Consequently, one to 3 patients

with positive dipstick (1+) could be falsely considered to be at high cardiovascular and kidney risk.

Several studies reported the poor sensitivity of dipstick testing to identify early renal disease in HIV-population [9], hypertensive [21] and diabetic patients [22]. A recent study has demonstrated that the sensitivity of dipstick test, may be affected by urinary concentration [9]. In addition, dipstick tests may miss about one out of five people with kidney disease, and positive dipstick test results for proteinuria may have to be confirmed by other laboratory tests [23]. In fact, in a study of 166 HIV-infected persons who underwent both a urine dipstick and a spot urine protein-to-creatinine ratio within a 48-hour period, 21% of those with low but overt proteinuria (300 to 900 mg/g creatinine) were not detected by urine dipstick. So, in individuals at renal risk, such as HIV + patients, the search for microalbuminuria is recommended when the dipstick is negative. Furthermore, the recent Kidney Disease Initiative and Global Outcome (KDIGO) CKD Guidelines recommend, in individuals with proteinuria by dipstick, to perform confirmatory protein quantification within 3 months [24]. Defining proteinuria as a positive urine dipstick test on two occasions [25] could have reduced the false positive rate in our study, but probably at the expense of an even higher false negative rate.

Conclusion

Strengths of the study

Because of the high prevalence of proteinuria, early screening efforts should be encouraged in HIV-patients both before and under antiretroviral treatment. Based on the accuracy of the semi-quantitative urine dipstick, the KDIGO CKD Guidelines suggest the use of either a spot protein-to-creatinine or spot albumin-to-creatinine ratio for kidney disease screening [24]. The results of the current study question the use of the urine dipstick as screening tool for low-level proteinuria in HIV patients. Although dipstick testing would decrease costs, it would fail to diagnose most patients with microalbuminuria, an early marker of glomerular injury. Therefore, HIV +

Table 4 Comparison between the dipstick and the ACR in 235 patients

Urine dipstick	A/C ratio (mg/g)			Total
	<30	30-299	≥ 300	
	n = 210	n = 21	n = 4	n = 235
0	128	10	0	138
1+	76	10	1	87
≥ 2+	6	1	3	10

(*) The numbers with gray shading correspond to false-positive dipstick results. The numbers highlighted in orange are false-negative ones.

patients with negative dipstick should be screened for microalbuminuria. The Infectious Diseases Society of America (IDSA) guidelines that recommend using the dipstick as a screening tool may need to be revisited and updated.

Limitations of the study

It is a cross-sectional study of consecutively recruited patients with a single measurement (serum creatinine and proteinuria) and a relatively small sample size, thus limiting the generalization of the results to the entire population of patients living with AIDS. In addition, patients naive to ART were also underrepresented limiting the generalization of results obtained.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SK participated in the design of the study and performed the statistical analysis; MJ conceived the study and participated in its design and coordination; KM has been involved in revising critically the manuscript; PW has been involved in revising critically the manuscript; MR participated in the design of the study and has been involved in revising critically the manuscript; LF has been involved in revising critically the manuscript; NN participated in the design of the study and has been involved in revising critically the manuscript; All authors read and approved the final manuscript.

Acknowledgements

- VLIR project/UCB for the material support in the achievement of all urine tests of this study;
- Department of Medical Biology of Cliniques Saint Luc/Brussels, for the calibration of serum creatinine;
- Department of Nephrology of Cliniques Saint Luc/Brussels, for financial support for some blood tests.

Author details

¹Department of Medicine, Université Catholique de Bukavu, Bukavu, DR Congo. ²Nephrology Unit, Department of Medicine, Université de Kinshasa, Kinshasa, DR Congo. ³Department of Nephrology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. ⁴Clinical Chemistry Department, Cliniques Universitaires St Luc, Louvain Center for Toxicology And Applied Pharmacology, Université Catholique de Louvain, Brussels, Belgium. ⁵Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. ⁶Postal address: 103 Cyangugu, Rwanda.

Received: 22 May 2014 Accepted: 28 August 2014

Published: 5 September 2014

References

1. Cailhol J, Nkurunziza B, Izzedine H, Nindagiye E, Munyana L, Baramperanye E, Nzorijana J, Sakubu D, Niyongabo T, Bouchaud O: **Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a cross-sectional study.** *BMC Nephrol* 2011, **2**:40.
2. Emem CP, Arogundade F, Sanusi A, Adelusola K, Wokoma F, Akinsola A: **Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors.** *Nephrol Dial Transplant* 2008, **23**(2):741–746.
3. Taal MW, Brenner BM: **Predicting initiation and progression of chronic kidney disease: developing renal risk scores.** *Kidney Int* 2006, **70**(10):1694–1705.
4. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: **Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data.** *Ann Intern Med* 2001, **135**(2):73–87.
5. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, Fields TA, Svetkey LP, Flanagan KH, Klotman PE, Winston JA: **The clinical**

- epidemiology and course of the spectrum of renal diseases associated with HIV infection. *Kidney Int* 2004, **66**(3):1145–1152.
6. Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, Klotman PE, D'Agati VD: **The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy.** *Kidney Int* 2009, **75**(4):428–434.
7. Gupta SK, Eustace JA, Winston JA, Boydston II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ, Lennox JL, Klotman PE, Nachman SA, Hall SD, Szczech LA: **Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.** *Clin Infect Dis* 2005, **40**(11):1559–1585.
8. Ginsberg JM, Chang BS, Matarese RA, Garella S: **Use of single voided urine samples to estimate quantitative proteinuria.** *N Engl J Med* 1983, **309**(25):1543–1546.
9. Siedner MJ, Atta MG, Lucas GM, Perazella MA, Fine DM: **Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients.** *J Acquir Immune Defic Syndr* 2008, **47**(2):261–263.
10. Glynn JR, Carael M, Auvert B, Kahindo M, Chege J, Musonda R, Kaona F, Buve A: **Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia.** *AIDS* 2001, **15**(Suppl 4):S51–S60.
11. Morison L: **The global epidemiology of HIV/AIDS.** *Br Med Bull* 2001, **58**:7–18.
12. Fabian J, Naicker S, Venter WD, Baker L, Naidoo S, Paget G, Wadde S: **Urinary screening abnormalities in antiretroviral-naive HIV-infected outpatients and implications for management—a single-center study in South Africa.** *Ethn Dis* 2009, **19**(1 Suppl 1):S180–S185.
13. Jao J, Palmer D, Leus I, Tih P, Baweja M, Klotman M, Sperling R, Wyatt C: **Prevalence and predictors of proteinuria in HIV-infected and uninfected pregnant women in Cameroon.** *Nephrol Dial Transplant* 2011, **26**(9):3051–3053.
14. Struik GM, den Exter RA, Munthali C, Chipeta D, Van Oosterhout JJ, Nouwen JL, Allain TJ: **The prevalence of renal impairment among adults with early HIV disease in Blantyre, Malawi.** *Int J STD AIDS* 2011, **22**(8):457–462.
15. Longo AL, Lepira FB, Sumaili EK, Makulo JR, Mukumbi H, Bukabau JB, Mokoli VM, Kayembe PK, Nseka NM: **Prevalence of low estimated glomerular filtration rate, proteinuria, and associated risk factors among HIV-infected black patients using Cockcroft-Gault and modification of diet in renal disease study equations.** *J Acquir Immune Defic Syndr* 2011, **59**(1):59–64.
16. Baekken M, Os I, Sandvik L, Oektedalen O: **Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population.** *Nephrol Dial Transplant* 2008, **23**(10):3130–3137.
17. Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, Wohl D, Shlipak MG: **Microalbuminuria in HIV infection.** *AIDS* 2007, **21**(8):1003–1009.
18. Kimmel PL, Umama WO, Bosch JP: **Abnormal urinary protein excretion in HIV-infected patients.** *Clin Nephrol* 1993, **39**(1):17–21.
19. Han TM, Naicker S, Ramdial PK, Assounga AG: **A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa.** *Kidney Int* 2006, **69**(12):2243–2250.
20. Hurlimann D, Weber R, Enseleit F, Luscher TF: **HIV infection, antiretroviral therapy, and endothelium.** *Herz* 2005, **30**(6):472–480.
21. Zeller A, Sigle JP, Battegay E, Martina B: **Value of a standard urinary dipstick test for detecting microalbuminuria in patients with newly diagnosed hypertension.** *Swiss Med Wkly* 2005, **135**(3–4):57–61.
22. Garcia C, Bordier L, Burnat P, Ceppa F, Dupuy O, Mayaudon H, Bauduceau B: **Urinary dipsticks must not be used to detect diabetes-induced incipient nephropathy.** *Presse Med* 2006, **35**(7–8):1117–1121.
23. Giacometti V, Erba P, Di Nello F, Coletto S, Viganò A, Zuccotti G: **Proteinuria in paediatric patients with human immunodeficiency virus infection.** *World J Clin Cases* 2013, **1**(1):13–18.
24. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: **KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.** *Kidney Int* 2013, **3**:1–150.
25. Cavalcanti MA, Coelho SN, Lacerda HR: **Prevalence of persistent proteinuria in stable HIV/AIDS patients and its association with HIV nephropathy.** *Braz J Infect Dis* 2007, **11**(5):456–461.

doi:10.1186/1471-2369-15-146

Cite this article as: Masimango et al.: Prevalence of microalbuminuria and diagnostic value of dipstick proteinuria in outpatients from HIV clinics in Bukavu, the Democratic Republic of Congo. *BMC Nephrology* 2014 **15**:146.